Smart drug delivery platform based on cell-derived vesicles
Smart drug delivery platform based on cell-derived vesicles
Nov 7, 2022 MDimune, Inc. announced a business agreement with EUMC and acquisition of IP from EUMC to develop therapeutics for inflammatory bowel diseases (IBD).
Oct 24, 2022 MDimune, Inc. enters into an MOU with SensoryCure to collaborate on the development of therapeutics for hearing loss .
Sep 15, 2022 Caravan Biologix and MDimune announced their collaboration to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers.
Cryo-TEM images of CDVs and EVs